Gain Therapeutics, Inc.
GANX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.26
KIRA · Stoqly’s AI analyst, in plain words
- Gain Therapeutics, Inc. lost $20.2M in fiscal 2025.
- Gain Therapeutics, Inc. has $20.4M more cash than debt.
Market cap
$54.0M
P/E
—
Revenue
—
Net income
−$20.2M
Free cash flow
—
Operating margin
—
Gain Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$20.2M
No. It lost money last year.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Gain Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Gain Therapeutics, Inc.
- CIK
- 0001819411
Gain Therapeutics, Inc. · GANX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.2M | $0.1M | $0.1M | — | — |
| Revenue growth | 470.9% | −15.1% | −60.6% | — | — |
| Net interest income | $0.0M | $0.4M | $0.5M | — | — |
| Operating margin | −8,379.5% | −12,688.8% | −40,313.6% | — | — |
| Net income | −$13.9M | −$17.6M | −$22.3M | −$20.4M | −$20.2M |
| Net margin | −8,418.5% | −12,555.8% | −40,339.7% | — | — |
| Diluted EPS | −$1.37 | −$1.48 | −$1.71 | −$0.89 | −$0.61 |
| Cash | |||||
| Cash from operations | −$12.4M | −$14.7M | −$18.9M | −$18.9M | −$18.5M |
| Capital expenditure | $0.1M | $0.1M | $0.0M | $0.0M | — |
| Free cash flow | −$12.5M | −$14.8M | −$18.9M | −$18.9M | — |
| FCF margin | −7,551.5% | −10,571.8% | −34,205.3% | — | — |
| Share count change | 279.1% | 16.9% | 9.5% | 75.9% | 44.1% |
| Debt and strength | |||||
| Cash and short-term investments | $36.9M | $20.1M | $16.8M | $10.4M | $20.8M |
| Debt incl. finance leases | $0.7M | $0.6M | $0.6M | $0.4M | $0.4M |
| Shareholders' equity | $34.8M | $18.9M | $12.6M | $7.3M | $18.6M |
| Current ratio | 14.8x | 5.1x | 3.6x | 3.0x | 6.6x |
| Returns and quality | |||||
| Return on equity | −67.7% | −65.5% | −141.6% | −205.0% | −155.7% |
| Return on tangible equity | −39.9% | −93.2% | −177.0% | −278.1% | −108.6% |
| Piotroski F-score | 5 | 2 | 1 | 1 | 4 |
| Altman Z'' | 11.7 | 0.6 | −8.1 | −21.9 | −10.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Gain Therapeutics, Inc. · GANX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.26 a share, the company is worth $54.0M.
Source: SEC EDGAR XBRL filings (CIK 0001819411). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.